Industry News
Pricing changes, regulatory decisions, coverage shifts and market exits — dated to the development, not to when we wrote it.
37 dated developments affecting what semaglutide costs and who sells it. Most recent: We re-checked every compounded semaglutide price at source (2026-08-05).
Every item names its source and closes on what it changes for someone paying for treatment. Where a story is still moving — a proposed rule, an ongoing enforcement matter — the item says so rather than implying it is settled.
All-in monthly cost at 2.4 mg
Every story, newest first
We re-checked every compounded semaglutide price at source
Where we could compare a third-party figure with the provider's own page, the number usually moved — and it mo…
Novo cuts self-pay pen pricing to $349 a month
Direct cash pricing for the branded pen falls well below list, narrowing the gap compounded programmes have re…
Medicare access expands to a flat monthly co-pay
Eligible Part D beneficiaries gain a route that undercuts every compounded programme we track.…
Microdose semaglutide protocols spread, and they are not comparable
Fractional weekly doses below the labelled starting dose are sold at lower prices. They do not map onto the ap…
Membership stacking spreads across semaglutide programmes
Several platforms now split the charge into medication plus a mandatory platform fee.…
New entrants push compounded semaglutide toward $86 a month
A nationwide platform launched at $86 for compounded semaglutide, well below the established band.…
More employers drop weight-management GLP-1 coverage at renewal
Withdrawals land mid-treatment, and interruption is the mechanism that undoes results.…
FDA proposes excluding semaglutide from the 503B bulks list
If finalised, outsourcing facilities would lose a pathway for compounding at scale.…
Compounded semaglutide availability tightens again
Enforcement changes through spring 2026 left availability uneven and programme-dependent.…
Wegovy HD adds a 7.2 mg dose at $399 a month direct
A higher-dose option for patients who plateau, priced through the manufacturer's direct channel.…
State action against a telehealth company's own compounding pharmacy
When the platform and the pharmacy are the same business, an action against one lands on patients of the other…
First-month promotional rates published as ongoing prices
A recurring error across round-ups, and the likely origin of several wrong figures.…
Generic semaglutide launches in India and Canada
Patents lapsed across roughly ten markets in 2026. US patents run into the early 2030s.…
Hims closes its compounded semaglutide programme to new patients
Following a settlement with Novo Nordisk, one of the largest platforms exits compounded semaglutide.…
The same molecule, two brands, a sevenfold price gap
The reformulated oral semaglutide sells near $149 a month while the older Rybelsus brand still lists near $998…
FDA issues warning letters to compounded GLP-1 marketers
Several telehealth companies were cited over labelling and marketing claims rather than patient harm.…
Prepaid plans are where the money gets stuck
Multi-month discounts are real, and so is the fact that compounded medication is generally not refundable once…
Oral Wegovy launches for chronic weight management
An FDA-approved semaglutide tablet for weight loss reaches the market, with reported cash pricing from $149 a …
State boards tighten telehealth prescribing and non-resident pharmacy rules
Availability maps narrowed programme by programme, and the reasons were licensure rather than clinical.…
Cardiovascular indication becomes the reliable coverage route
Payers that exclude weight management routinely cover the same molecule for cardiovascular risk reduction.…
Telehealth platforms restructure around brand-only models
Membership billed separately from medication became the dominant structure at the large consumer platforms.…
FDA issues more than 55 warning letters to online GLP-1 sellers
The agency targeted direct-to-consumer advertising by compounded semaglutide and tirzepatide marketers.…
Semaglutide approved for MASH with moderate to advanced fibrosis
The first GLP-1 with an FDA liver indication, on accelerated approval, for a narrow population.…
Summer shipping is the season for cold-chain failures
Warm arrivals cluster in the hottest months, and most programmes put the judgement call on the patient.…
Novo Nordisk sues a major telehealth platform over compounded semaglutide
Litigation between the manufacturer and the largest consumer platforms reshaped the market faster than regulat…
Alerts continue on counterfeit product and research-labelled peptide
Two different problems, one outcome: an unverified substance in a syringe.…
Pharmacies pivot to B12 combinations after the April deadline
Semaglutide combined with another active ingredient is argued not to be essentially a copy. The status is unse…
The 503B deadline passes, closing large-scale semaglutide compounding
Outsourcing facilities lose the shortage exception a month after 503A pharmacies.…
Court declines to block the semaglutide compounding wind-down
A district court denied the preliminary injunction sought by an outsourcing-facility trade group, leaving FDA'…
The 503A deadline passes for compounded semaglutide
State-licensed pharmacies lose the shortage exception that permitted copies of Ozempic and Wegovy.…
FDA flags unapproved salt forms of semaglutide
Semaglutide sodium and semaglutide acetate are not the same as the base peptide, and the agency has linked the…
FDA sets the wind-down clock for compounded semaglutide
The agency published transition deadlines: 60 days for state-licensed pharmacies and 90 days for outsourcing f…
NovoCare Pharmacy opens a direct cash channel
The manufacturer begins selling to cash-paying patients directly, from a reported $149 for some products.…
FDA declares the semaglutide shortage resolved
The declaration narrowed lawful compounding to the patient-specific 503A pathway and set the deadlines that re…
Wegovy supply normalises after two years of constraint
Manufacturing capacity caught up with demand, which set up the February shortage resolution.…
Compounded versions reached roughly 30% of US GLP-1 supply
The scale of the compounded market at its 2024 peak explains how much had to restructure in 2025.…
Wegovy gains a cardiovascular risk-reduction indication
The SELECT trial produced an indication that is frequently easier to get covered than weight management alone.…
Open these rather than taking our word for it. Every one is a regulator, a trial registry, a label, an accreditor or the manufacturer.
Compare every programme on one screen
The matrix carries all-in price at every dose, fee structure, commitment terms, pharmacy disclosure and verification status for every programme we track.